Drug resistance mechanisms create targetable proteostatic vulnerabilities in Her2+ breast cancers
K. Komurov, N. Singh, L. Privette-Vinnedge
This study identifies proteostatic vulnerabilities in Her2+ breast cancers during resistance to Her2 inhibitors, showing that targeting ER quality control can overcome resistance.
bioRxiv · Aug 18, 2021 · PreprintCancer Biology